UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~September~~December 1231, 2025

HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in charter)

GA	333-62216	74-3002154
GEORGIA	333-62216	74-3002154
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2002 SUMMIT BLVD, SUITE 300
ATLANTA, GA		30319
(Address of principal executive offices)		(Zip Code)

(404) 566-4865

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act.

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	HDVY	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 78.01 ~~Regulation~~Other ~~FD Disclosure~~Events

On ~~September~~December 1231, 2025, Health Discovery Corporation ~~issued~~ a(the ~~letter~~“Company”) tofiled ~~its~~a ~~shareholders~~patent ~~providing~~infringement anlawsuit ~~update~~against toNVIDIA Corporation (“NVIDIA”) in the ~~Company’s~~United ~~recent~~States ~~activity,~~District aCourt ~~copy~~for the District of ~~which~~Delaware. isThe ~~furnished~~lawsuit ~~herewith~~seeks legal and equitable relief based on NVIDIA’s asunlawful ~~Exhibit~~infringement 99of U.1S. Patent No. 10,402,685 (the “‘685 Patent”) which generally relates to ~~this~~Recursive ~~Current~~Feature Elimination ~~Report~~Method onUsing ~~Form~~Support ~~8-K~~Vector ~~and~~Machines isfor ~~incorporated~~selecting byfeatures ~~reference~~from ~~into~~a ~~this~~dataset ~~Item~~to ~~7.01~~improve bypattern ~~reference~~recognition and classification tasks.

InThe ~~accordance~~claimed ~~with~~invention ~~General Instruction B.2~~ of ~~Form 8-K,~~ the ‘685 ~~information~~Patent inintroduces ~~this~~a ~~Item~~recursive ~~7.01~~training ofand ~~this~~elimination ~~Current~~process ~~Report~~that onsystematically ~~Form~~ranks ~~8-K,~~data ~~including~~features ~~the~~by ~~information~~their ~~set forth in Exhibit 99.1,~~contribution isto ~~being~~model ~~furnished~~accuracy and ~~shall~~removes ~~not~~the beleast ~~deemed~~significant ~~“filed”~~ones. ~~for~~This ~~purposes~~approach ofallows ~~Section~~a 18learning ofsystem ~~the~~not ~~Exchange~~only ~~Act,~~to ~~nor~~classify ~~shall~~data, itbut beto ~~deemed~~intelligently ~~incorporated~~refine ~~by reference in any filing under~~ the ~~Securities~~data ~~Act~~representation ~~or the Exchange Act~~itself, ~~except~~thereby asyielding ~~shall~~a bemore ~~expressly~~efficient, ~~set~~interpretable ~~forth~~and bygeneralizable ~~specific reference in such a filing~~model.

~~Item~~In 9summary, the lawsuit asserts that NVIDIA infringes, at least, representative method claim 1 of the ‘685 Patent through its GPU-accelerated machine-learning stack.01 The ~~Financial~~‘685 ~~Statements~~Patent expired on or about June 27, 2025, but the Company is seeking damages and ~~Exhibits~~other relief for the period for which the statute of limitations on the infringement claim has not yet expired. The Company is seeking, among other relief, trebled damages based on NVIDIA’s willful and deliberate infringement.

~~(d)~~There ~~Exhibits~~can be no assurance as to the outcome of this litigation or the timetable for bringing this case to trial.

~~99.1 Letter to Shareholders~~2

~~104 Cover Page Interactive Data File (embedded within the Inline XBRL document)~~SIGNATURES

2Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIGNATURES

	HEALTH DISCOVERY CORPORATION
	Registrant

Dated: January 21, 2026	By:	/s/ Alan K. Hauser
		Alan K. Hauser Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~3

	HEALTH DISCOVERY CORPORATION
	Registrant
Dated: September 12, 2025	By:	/s/ Alan K. Hauser
		Alan K. Hauser Chief Executive Officer

Filing Compare · HEALTH DISCOVERY CORP